The effect of anti-IL5 monoclonal antibodies on regulatory and effector T cells in severe eosinophilic asthma
Introduction: Biological treatments have redesigned the clinical management of severe eosinophilic asthmatic (SA) patients. Despite emerging evidence supporting the role of natural Killer (NK), and T regulatory cells (Treg) in the pathogenesis of asthma, no data is available on the effects of anti-I...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-10-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223011824 |
| _version_ | 1797686849991344128 |
|---|---|
| author | Laura Bergantini Tommaso Pianigiani Miriana d’Alessandro Sara Gangi Behar Cekorja Elena Bargagli Paolo Cameli |
| author_facet | Laura Bergantini Tommaso Pianigiani Miriana d’Alessandro Sara Gangi Behar Cekorja Elena Bargagli Paolo Cameli |
| author_sort | Laura Bergantini |
| collection | DOAJ |
| description | Introduction: Biological treatments have redesigned the clinical management of severe eosinophilic asthmatic (SA) patients. Despite emerging evidence supporting the role of natural Killer (NK), and T regulatory cells (Treg) in the pathogenesis of asthma, no data is available on the effects of anti-IL5/IL5R therapies on these cell subsets. Methods: We prospectively enrolled fourteen SA patients treated with benralizumab (n = 7) or mepolizumab (n = 7) and compared them with healthy controls (HC) (n = 11) and mild to moderate asthmatic (MM) patients (n = 9). Clinical parameters were collected at baseline (T0) and during follow-up. Cellular analysis, including the analysis of T/NK cell subsets, was determined through multicolor flow cytometry. Results: At T0, SA patients showed higher percentages of CD4 TEM (33.3 ± 17.9 HC, 42.6 ± 16.6 MM and 66.1 ± 19.7 in SA; p < 0.0001) than HC and MM patients. With different timing, the two drugs induce a reduction of CD4 TEM ( 76 ± 19 T0; 43 ± 14 T1; 45 ± 23 T6; 62 ± 18 at T24; p < 0.0001 for mepolizumab and 55 ± 21 T0; 55 ± 22 T1; 43 ± 14 T6; 27 ± 12 at T24; p < 0.0001 for benralizumab) and an increase of Treg cells (1.2 ± 1.3 T0; 5.1 ± 2.5 T1; 6.3 ± 3.4 T6; 8.4 ± 4.6 at T24; p < 0.0001 for mepolizumab and 3.4 ± 1.7 T0; 1.9 ± 0.8 T1; 1.9 ± 1 T6; 5.1 ± 2.4 at T24; p < 0.0001 for benralizumab). The change of CD56dim PD-1+ significantly correlated with FEV1% (r = − 0.32; p < 0.01), while Treg expressing PD-1 correlates with the use of oral steroids ( r = 0.36 p = 0.0008) and ACT score (r = 0.36 p = 0.0008) p < 0.001) Conclusions: Beyond the clinical improvement, anti-IL-5 treatment induces a rebalancing of Treg and T effector cells in patients with SA |
| first_indexed | 2024-03-12T01:10:34Z |
| format | Article |
| id | doaj.art-3ac3d60824c44c99ad9a1b94cdfe0de9 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-03-12T01:10:34Z |
| publishDate | 2023-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-3ac3d60824c44c99ad9a1b94cdfe0de92023-09-14T04:52:51ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-10-01166115385The effect of anti-IL5 monoclonal antibodies on regulatory and effector T cells in severe eosinophilic asthmaLaura Bergantini0Tommaso Pianigiani1Miriana d’Alessandro2Sara Gangi3Behar Cekorja4Elena Bargagli5Paolo Cameli6Correspondence to: Department of Medical Sciences, Surgery and Neurosciences, Respiratory Disease and Lung Transplant Unit, Siena University, 53100 Siena, Italy.; Respiratory Disease Unit, Department of Medical Sciences, University Hospital of Siena (Azienda Ospedaliero Universitaria Senese, AOUS), Viale Bracci, 53100 Siena, ItalyCorrespondence to: Department of Medical Sciences, Surgery and Neurosciences, Respiratory Disease and Lung Transplant Unit, Siena University, 53100 Siena, Italy.; Respiratory Disease Unit, Department of Medical Sciences, University Hospital of Siena (Azienda Ospedaliero Universitaria Senese, AOUS), Viale Bracci, 53100 Siena, ItalyRespiratory Disease Unit, Department of Medical Sciences, University Hospital of Siena (Azienda Ospedaliero Universitaria Senese, AOUS), Viale Bracci, 53100 Siena, ItalyRespiratory Disease Unit, Department of Medical Sciences, University Hospital of Siena (Azienda Ospedaliero Universitaria Senese, AOUS), Viale Bracci, 53100 Siena, ItalyRespiratory Disease Unit, Department of Medical Sciences, University Hospital of Siena (Azienda Ospedaliero Universitaria Senese, AOUS), Viale Bracci, 53100 Siena, ItalyRespiratory Disease Unit, Department of Medical Sciences, University Hospital of Siena (Azienda Ospedaliero Universitaria Senese, AOUS), Viale Bracci, 53100 Siena, ItalyRespiratory Disease Unit, Department of Medical Sciences, University Hospital of Siena (Azienda Ospedaliero Universitaria Senese, AOUS), Viale Bracci, 53100 Siena, ItalyIntroduction: Biological treatments have redesigned the clinical management of severe eosinophilic asthmatic (SA) patients. Despite emerging evidence supporting the role of natural Killer (NK), and T regulatory cells (Treg) in the pathogenesis of asthma, no data is available on the effects of anti-IL5/IL5R therapies on these cell subsets. Methods: We prospectively enrolled fourteen SA patients treated with benralizumab (n = 7) or mepolizumab (n = 7) and compared them with healthy controls (HC) (n = 11) and mild to moderate asthmatic (MM) patients (n = 9). Clinical parameters were collected at baseline (T0) and during follow-up. Cellular analysis, including the analysis of T/NK cell subsets, was determined through multicolor flow cytometry. Results: At T0, SA patients showed higher percentages of CD4 TEM (33.3 ± 17.9 HC, 42.6 ± 16.6 MM and 66.1 ± 19.7 in SA; p < 0.0001) than HC and MM patients. With different timing, the two drugs induce a reduction of CD4 TEM ( 76 ± 19 T0; 43 ± 14 T1; 45 ± 23 T6; 62 ± 18 at T24; p < 0.0001 for mepolizumab and 55 ± 21 T0; 55 ± 22 T1; 43 ± 14 T6; 27 ± 12 at T24; p < 0.0001 for benralizumab) and an increase of Treg cells (1.2 ± 1.3 T0; 5.1 ± 2.5 T1; 6.3 ± 3.4 T6; 8.4 ± 4.6 at T24; p < 0.0001 for mepolizumab and 3.4 ± 1.7 T0; 1.9 ± 0.8 T1; 1.9 ± 1 T6; 5.1 ± 2.4 at T24; p < 0.0001 for benralizumab). The change of CD56dim PD-1+ significantly correlated with FEV1% (r = − 0.32; p < 0.01), while Treg expressing PD-1 correlates with the use of oral steroids ( r = 0.36 p = 0.0008) and ACT score (r = 0.36 p = 0.0008) p < 0.001) Conclusions: Beyond the clinical improvement, anti-IL-5 treatment induces a rebalancing of Treg and T effector cells in patients with SAhttp://www.sciencedirect.com/science/article/pii/S0753332223011824BenralizumabMepolizumabSevere asthmaRegulatory T cellsImmune checkpoints |
| spellingShingle | Laura Bergantini Tommaso Pianigiani Miriana d’Alessandro Sara Gangi Behar Cekorja Elena Bargagli Paolo Cameli The effect of anti-IL5 monoclonal antibodies on regulatory and effector T cells in severe eosinophilic asthma Biomedicine & Pharmacotherapy Benralizumab Mepolizumab Severe asthma Regulatory T cells Immune checkpoints |
| title | The effect of anti-IL5 monoclonal antibodies on regulatory and effector T cells in severe eosinophilic asthma |
| title_full | The effect of anti-IL5 monoclonal antibodies on regulatory and effector T cells in severe eosinophilic asthma |
| title_fullStr | The effect of anti-IL5 monoclonal antibodies on regulatory and effector T cells in severe eosinophilic asthma |
| title_full_unstemmed | The effect of anti-IL5 monoclonal antibodies on regulatory and effector T cells in severe eosinophilic asthma |
| title_short | The effect of anti-IL5 monoclonal antibodies on regulatory and effector T cells in severe eosinophilic asthma |
| title_sort | effect of anti il5 monoclonal antibodies on regulatory and effector t cells in severe eosinophilic asthma |
| topic | Benralizumab Mepolizumab Severe asthma Regulatory T cells Immune checkpoints |
| url | http://www.sciencedirect.com/science/article/pii/S0753332223011824 |
| work_keys_str_mv | AT laurabergantini theeffectofantiil5monoclonalantibodiesonregulatoryandeffectortcellsinsevereeosinophilicasthma AT tommasopianigiani theeffectofantiil5monoclonalantibodiesonregulatoryandeffectortcellsinsevereeosinophilicasthma AT mirianadalessandro theeffectofantiil5monoclonalantibodiesonregulatoryandeffectortcellsinsevereeosinophilicasthma AT saragangi theeffectofantiil5monoclonalantibodiesonregulatoryandeffectortcellsinsevereeosinophilicasthma AT beharcekorja theeffectofantiil5monoclonalantibodiesonregulatoryandeffectortcellsinsevereeosinophilicasthma AT elenabargagli theeffectofantiil5monoclonalantibodiesonregulatoryandeffectortcellsinsevereeosinophilicasthma AT paolocameli theeffectofantiil5monoclonalantibodiesonregulatoryandeffectortcellsinsevereeosinophilicasthma AT laurabergantini effectofantiil5monoclonalantibodiesonregulatoryandeffectortcellsinsevereeosinophilicasthma AT tommasopianigiani effectofantiil5monoclonalantibodiesonregulatoryandeffectortcellsinsevereeosinophilicasthma AT mirianadalessandro effectofantiil5monoclonalantibodiesonregulatoryandeffectortcellsinsevereeosinophilicasthma AT saragangi effectofantiil5monoclonalantibodiesonregulatoryandeffectortcellsinsevereeosinophilicasthma AT beharcekorja effectofantiil5monoclonalantibodiesonregulatoryandeffectortcellsinsevereeosinophilicasthma AT elenabargagli effectofantiil5monoclonalantibodiesonregulatoryandeffectortcellsinsevereeosinophilicasthma AT paolocameli effectofantiil5monoclonalantibodiesonregulatoryandeffectortcellsinsevereeosinophilicasthma |